Imdelltra Combo Data Adds Optionality but Doesn't Change Amgen's Risk-Reward

What happened

Amgen's bispecific T-cell engager Imdelltra (tarlatamab) demonstrated a 58% reduction in risk of death when combined with AstraZeneca's PD-L1 inhibitor Imfinzi (durvalumab) in advanced lung cancer, according to new data highlighted by The Motley Fool. This represents a potential expansion opportunity for Imdelltra beyond its current accelerated approval in extensive-stage small cell lung cancer, where it is a niche therapy, into broader non-small cell lung cancer settings that would materially enlarge its commercial runway. The result adds a new growth vector to Amgen's oncology franchise, which the latest DeepValue report identifies as a supporting driver but not the primary thesis, which remains dominated by MariTide (obesity) and management of legacy product erosion. However, the announcement lacks detailed trial design, patient population, and safety data, and any regulatory filing or approval is years away, meaning it does not alter near-term earnings or the current overhang from IRA price cuts, biosimilars, and elevated leverage. Overall, the news modestly improves the long-term optionality of Imdelltra but is insufficient to change the POTENTIAL SELL rating given the stock's rich valuation (~23.7x earnings) and near-term headwinds.

Implication

For investors, the combination data for Imdelltra and Imfinzi is a welcome sign that Amgen's oncology pipeline can expand into larger indications, but it is still early-stage and subject to confirmation. The current valuation already prices in substantial growth from existing portfolio and obesity, so any upside from Imdelltra expansion is likely to be incremental rather than a step-change. Investors should not chase the stock on this news alone, as the fundamental challenges of ENBREL/Otezla/Prolia erosion, biosimilar competition, and tax disputes remain unchanged. A more attractive entry point would be closer to the $295 level identified in the report, where the risk-reward would better reflect uncertainty around MariTide and pipeline execution. Over the next 6-12 months, watch for additional data releases, including Phase 3 results for Imdelltra combinations and MariTide readouts, which will be the key catalysts.

Thesis delta

The positive Imdelltra/Imfinzi combination data adds a new growth avenue for Amgen's oncology franchise, marginally increasing the probability that Imdelltra can expand beyond its current niche in small cell lung cancer. However, this does not address the core risks of policy-driven price erosion, MariTide clinical uncertainty, and elevated leverage that underpin the POTENTIAL SELL rating. The thesis is unchanged: risk-reward remains skewed to the downside at current levels, with a better entry near $295.